Ascendis Pharma A/S (ASND)

Every figure this model derived for ASND, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-09-30
cash 616,041,000 CashAndCashEquivalents 2025-12-31
current assets 1,108,985,000 CurrentAssets 2025-12-31
current liabilities 1,069,391,000 CurrentLiabilities 2025-12-31
equity -162,821,000 Equity 2025-12-31
interest expense 206,688,000 FinanceCosts 2025-12-31
ocf 53,897,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 720,133,000 Revenue 2025-12-31
sbc 116,171,000 AdjustmentsForSharebasedPayments 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ASND on one particular measure came for.

RatioValue
cash operating margin-0.4
current ratio1.04
current ratio reported1.04
dilution pct4.69
fcf margin7.48
interest cover-0.66
operating margin-18.92
owner earnings margin-8.65
revenue growth98.03
revenue growth per share89.16
roic-20.61
rule of 4079.11
sbc pct revenue16.13

What to be careful about

What this model itself distrusts about ASND's figures. Written by the derivation as it ran, not added afterwards.